The concern of the public regarding terrorist actions involving nuclear emergencies resulted in the reopening of the discussion regarding the best ways to cope with the inevitable health impairments. Medical experts from the US and from Europe considered it of importance to harmonize at an international level the diagnostic and therapeutic approaches regarding the radiation-induced health impairments. The present contribution is the result of the first U.S./European Consultation Workshop addressing approaches to radiation emergency preparedness and assistance, which was held recently at
INTRODUCTION
The scope and purpose of this consultation workshop was to bring together a group of experts in the field of the medical management of radiation accident victims to discuss and compare the emergency approaches used in the US and in the countries of the European Community. There is an agreement that there was an urgent need on both sides of the Atlantic to try to achieve a sound and scientifically based harmonization of efforts and methods regarding the clinical management of radiation accident victims. These methods are critical if there is to be strong and active international cooperation.
Discussions centered on the assessment of the extent of damage after total body irradiation to the hematopoietic damage, especially of the stem and progenitor cell pools as a prerequisite for the decision regarding hematopoietic stem cell transplantation (HSCT). A second topic was related to the fact that any total body irradiation will be the result of the involvement of all cells and tissues on the basis of their biological properties (multiorgan involvement resulting potentially in multiorgan failure). A third topic arose from the need to have and develop further approaches to determine appropriate ''triage''-the prognosis of each of the victims involved as a basis for appropriate therapeutic measures.
Furthermore, these discussions lead to the conclusion-a fourth topic-that it would be necessary and inevitable to review the opportunities for the appropriate clinical training of medical and nursing staff to ''be prepared'' including international cooperation. In addition, there was a consensus on the need for a strong international cooperation in research and development regarding several aspects of radiation emergency medical preparedness and assistance. As such, all these efforts remain a work in progress and will continue to improve as we learn more about possible radiation mitigators, biological indicators of effect and repair, and dosimetry as well as shielding efforts.
BACKGROUND: THE NEED TO HARMONIZE RADIATION EMERGENCY MEDICAL PREPAREDNESS AND ASSISTANCE AT AN INTERNATIONAL LEVEL
The citizens as well as the public health and medical communities in the U.S. and Europe remain concerned that our societies are not adequately prepared for large scale criminal or terrorist activities involving radiation. Specialists from the radiation medicine scientific medical community consider it a privilege and responsibility to lead preparedness efforts to provide the best possible care in such acts of terrorism or catastrophic failures [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . Victim care would most likely be coordinated by trauma specialists in close contact with hematology and oncology experts because of their familiarity with hematopoietic toxicities. Although various approaches for optimal treatments have been proposed, there is not complete consensus. Animal models of exposure and countermeasures are helpful but may not be fully applicable to the mass casualty setting, with additional information needed on combined injury of radiation plus physical injury.
In In Europe, the EU Commission is authorized to provide only framework regulations for a response. The creation and execution of specific response plans are left to each national government. Thus, there is no overall European plan to create a radiation syndrome oriented uniform policy and no financial means to enhance appropriate medical and response competence in European hospitals beyond what is available on the basis of each country's own risk assessment. However, one professional medical society, the European Group for Blood and Marrow Transplantation (EBMT, http://www.ebmt.org), an association of more than 400 hospitals in Europe with extensive experience in stem cell transplantation and in treating patients suffering from very severe organ impairments, has established a ''Nuclear Accident Committee'' to develop preparedness research and training programs [1, [7] [8] [9] 12] .
On both sides of the Atlantic, there is a sense of ''joint responsibility'' to harmonize as much as feasible evidencebased nuclear accident medical preparedness. In this spirit, the U.S./European Consultation Workshop was conducted at the Science Conference Center of Ulm University ''Schloss Reisensburg'' to review the ''state of the arts'' for managing radiation victims. In particular, the purpose of this workshop was to bring together a group of experts in the medical management of radiation accident and terrorism victims to discuss the approaches used based on the European Medical Treatment Protocols for Radiation Accident (METREPOL) Response Category-Grading in Europe and those used in the U.S., some of which are summarized on Radiation Event Medical Management (REMM, http://www.remm.nlm.gov) web site.
The Consultation Workshop members recognized that there are major knowledge gaps in understanding the pathophysiology of the acute radiation syndromes (ARS) and the multiorgan dysfunction and failure that can result after significant whole or partial body radiation exposure [7] . It was agreed that new methods for earlier and more accurate diagnosis and treatment of ARS are needed, as well as better radiation mitigators, faster and more accurate biodosimetry tools, and a better understanding of partial body shielding effects. This expanded knowledge will assist in the care of victims in both small and large scale events.
The EBMT has developed diagnostic and management guidelines for the clinicians. These efforts were based on the METREPOL concept using the clinical response categories as the basis for clinical decision making [1, 9] . This concept is in part available on a web site of the Radiation Medicine Research Group of Ulm University. American proposals were initially developed by the Strategic National Stockpile Working Group [6] and further refined by NMDP and ASBMT working together in RITN (http://www.ritn.org). The current expert-based suggested management algorithms are available on the REMM web site, developed by the Office of the Assistant Secretary for Preparedness and Response, in the U.S. Department of Health and Human Services, in collaboration with the National Library of Medicine (NLM, http:// www.nlm.nih.gov).
The approaches used by EBMT and in the U.S. were felt to be different, but are complementary to each other. The major differences reflected in existing planning and response strategies were based on differences in the types of events being planned for, including differences in
• the exact planning scenario and its location in relation to population centers, • the type of event (E.G., Industrial accident, nuclear reactor meltdown, nuclear detonation) and • the size of the event (E.G., the Kiloton size of an improvised nuclear device).
It was recognized that differences in capacity and capability exist from country to country. They include the availability of
• medical expertise, • appropriate biodosimetry tools, • large scale laboratory facilities and • specifically designed clinical facilities.
ASSESSMENT OF HEMATOLOGICAL STEM AND PROGENITOR CELL DAMAGE AS A BASIS FOR PLANNING THERAPEUTIC STRATEGIES AND THE USE OF HSCT
There were extensive discussions on when and how to use HSCs to overcome radiation induced bone marrow failure. A review of the scientific literature, which is historically dated, indicated that this method of treatment has not resulted in significantly improved survival. Future use of HSCT in the management of unintended radiation exposure should follow established guidelines and ensure adequate data collection for evaluation of efficacy. There was a consensus that a HSCT should be considered if the victim's HSC pool is essentially irreversibly damaged (described below) and a suitable donor is available [1, 9] . It may also be considered when victims have reversible HSC injury but would likely succumb to complications of marrow failure before their marrow recovers.
Discussions confirmed that it is currently difficult to determine whether the HSC pool has a chance of autochthonous recovery. A more thorough understanding of the physiology of blood cell formation, its regulatory mechanisms and its repair potentialities is needed [14, 15] . As the bone marrow in adults is distributed throughout much of the skeleton and the stem cells are able to traffic throughout the body, bone marrow functions as one organ system. Therefore, homogeneity or heterogeneity of total body irradiation as well as the dose and dose rate of exposure plays a major role in the development of the radiation hematopoietic syndrome.
Assessment of the severity of hematopoietic injury by total body radiation exposure requires the use of ''indicators of exposure''; ''indicators of effect'' (and indicators of repair) (see publications of the U.S. National Academy of Sciences) [16, 17] . In a radiation accident, experts will provide physical measurements of radiation type, dose and dose rate in the environment. For victims, this needs to be translated into some measure of absorbed dose. The extent of hematopoietic damage after irradiation depends on the structure, function, and regulation of the bone marrow, where HSCs are very sensitive to radiation. Animal and human studies indicate that the pluripotent/pluripotent stem cell has a D 0 of about 95 cGy [18] . Therefore, if exposed to a truly myeloablative homogeneous total body exposure of about 6 Gy, one would expect that only 0.25% of cells in the stem cell pool would survive, or only about 2.5 per 1,000 cells. This dose would not only produce an arrest in the recruitment of cells from a stem cell/ progenitor cell pool, but would also impair and eliminate further proliferation and differentiation of precursor cells. For example, migration of granulocytes from the bone marrow to the circulation would be expected for about 4 days after radiation exposure, since the maturation time of granulocytes in the marrow is about 4 days [19] [20] [21] . Thus, after an acute radiation injury one observes prompt emptying of the entire granulocyte marrow reserve, resulting in the remarkable granulocytosis in the first 3-4 days after exposure, with granulocyte concentrations in the blood going up to even 30,000 per mm 3 during the first 4 days, partly driven by systemic endotoxins from GI injury. A granulocyte in the blood has a half-life of about 7 hours [21] , and the maximum life span of 24 hours [5] . Thus, after a significant irradiation in humans of 500-1,000 cGy, a dose-dependent granulocyte overshoot is observed, characteristic of mobilization of a granulocyte reserve. An extensive pathophysiological analysis of the early blood cell changes after radiation exposure is presented elsewhere [8] .
There was consensus that HSCT should be considered when the blood cell changes during the first days after radiation exposure are compatible with the severity grade H4 of the METREPOL approach (i.e., irreversible damage to stem cell pool) [1, 9] . If the constellation of blood cell changes early after exposure indicates the severity code is H3, H2, or H1, then the patient is likely to have a reversible damage to the stem cell pool and should be treated with supportive care to ''bridge'' the time of temporary hematopoietic failure with appropriate therapeutic measures. Using mathematical models of granulocytopoiesis, lymphopoiesis, and platelet production, a software program is being developed which takes input about radiation-induced early blood cell changes to assign a ''severity of hematologic damage grade'': H1, H2, H3, H4 [22] . Medical planning can then be based on the results of this graded output. In some cases of severe H3, HSCT may also be needed because the patient may succumb to complications before the marrow recovers and HSCT is needed as a bridging technique. Prior to transplantation, a bone marrow aspiration and biopsy should be performed from two different Fliedner, Chao, Bader et al. marrow sites, ideally in both high and low-dose regions, if that information is known, to confirm the status and to assess the likelihood of autologous recovery of the blood cell forming tissue [23] [24] [25] [26] [27] [28] [29] [30] [31] .
Another area of discussion was the bone marrow niche. It is known that the HSCs reside in close association with osteoblasts and sinusoidal blood vessels within the bone marrow and this association contributes to the maintenance of the HSC pool in vivo. Efforts to improve outcome for affected individuals should also focus on the stem cell niche. Several studies have demonstrated that bone marrow (BM) osteoblasts regulate HSC pool size in vivo via the Jagged1-Notch signaling pathway and pharmacologic activation of osteoblasts via treatment with parathyroid hormone (PTH) increases the mobilization of HSCs into the peripheral blood. PTH treatment can also protect BM HSCs from the deleterious effects of repeated cycles of cytotoxic chemotherapy raising the possibility that PTH might be useful in mitigation radiation injury as well. HSC and progenitor cells also reside in proximity to BM sinusoidal vessels in the adult, the so called vascular niche. Exposure to ionizing radiation or chemotherapy induces apoptosis of vascular endothelial cells in vitro and regression of BM sinusoidal vessels in vivo. Ionizing radiation also causes apoptosis of vascular endothelial cells in nonhematopoietic tissues, including the brain and intestinal tract. BM aplasia and regression of BM sinusoidal vessels developed simultaneously in rodents treated with 20 Gy limb irradiation and more importantly, recovery of hematopoiesis correlated temporally with BM vascular reorganization in vivo. Adult sources of vascular endothelial cells may therefore provide reparative or regenerative signals to BM HSCs which can facilitate hematopoietic recovery following myelotoxicity. As a subset of BM HSCs are highly radioresistant and potentially responsive to reparative signals from the BM niche, it is plausible that therapies to augment niche activity could accelerate hematopoietic recovery in vivo.
Except in rare instances where autologous HSCs would be available, allogeneic donors-related or unrelated, including cord blood-would be needed. International cooperation to harmonize the necessary approaches and methods of HSCT would be valuable. In US, current human leukocyte antigen (HLA) typing capacity from NMDP is 1,000 samples per day. If necessary, buccal mucosa cells can be used to identify the HLA type. It was stressed, that before using a stem cell transplant, the irreversibility of HSC damage should be documented which means that a transplant could not be ready before 14 days following the exposure. Patients with H4 have to receive optimal supportive care, including strict reverse isolation, antibiotics, antivirals, antifungals, platelet and blood transfusion, optimal control of fluid balance, etc. In the case of a large event, international cooperation would be important to optimize capacity. The METREPOL concept currently uses a multiorgan assessment to characterize clinical effects as a function of time after radiation exposure by grading the severity of effect of the four most relevant organ systems, in particular, the neurovascular system, the hematopoietic system, the gastrointestinal system, and the cutaneous system [1, 9] . The grade of the most severely affected organ system defines the ''response category'' which is used to determine where the patients should be optimally referred to for care. This approach is also helpful to determine the most likely complications to be expected and to select the most appropriate clinical services required. The Japanese experience in two patients of Tokai-mura indicated that all relevant organ systems will show their organ-specific picture and pattern of response to radiation [32] . These patients showed the course of signs and symptoms in a unique way as they appear if there is at least a transient recovery of the hematopoietic system. One of them survived for 83 days, the other for 211 days.
In the U.S./European Consultation Workshop a ''unifying hypothesis of the pathophysiology of the radiation syndromes'' was presented, suggesting possible future directions for understanding and treating radiation exposed persons [33, 34] . One important feature to be determined and/or developed was how soon after an exposure could the METREPOL be used to determine medical interventions and the use of medical countermeasures. In that case, the decision to initiate medical countermeasures needs to be made within the first few days for optimal efficacy and there may be tens of thousands of victims requiring triage in a mass casualty event, medical responders need a reasonably accurate system that requires limited data, limited numbers of observations, and ease of use. There was agreement in the workshop regarding such a multiorgan failure approach as a potentially useful pathophysiological way for therapeutic actions. Furthermore, it is apparent that the systematic use of such an approach is in itself of importance to initiate appropriate therapeutic approaches because the most important signs and symptoms of the damage caused in the four most important organ systems are systematically recorded.
A major part of the workshop dealt with the medical problems to be expected in patients with a potentially reversible damage of the blood cell formation. There was consensus that it was again the pattern of change in the blood cell lineages that dictates the clinical course to an important extent, because blood effects occur at doses generally lower than effects in other organ systems. It is important to realize that the pattern of blood cell changes in patient graded as H3, H2, and H1 follow the same principle. This pattern was observed first in the Oak Ridge patients in 1958 [15, 35] . In these patients (and in all patients observed later exposed in these dose ranges, such as in Chernobyl [36] , in some of the Chinese accidents [37] , the blood granulocytes show a moderate increase above normal during the first 3-4 days, then a declining tendency reaching granulocytopenic values between 5 and 8 days. Then the concentration remains below normal followed with a stable low count between days 10 and 15 or even a rebound increase (abortive rise). Thereafter, a second decrease phase is observed reaching a nadir between days 20 and 30 followed by a spontaneous recovery within days 30-50. Such a course of cell response is also seen in the red-cell series (in this case one has to observe the reticulocyte count) as well as in the megakaryocyte-platelet system. These patterns have been described and analyzed with biomathematical tools [15] . The consequences that can be expected after these typical blood cell concentration patterns dictate the clinical measures to be taken: risk of infection during the time of low granulocyte count, bleeding or even serious blood loss. For all these patients (and in a severe accident situation this may well be possible for the majority of patients) the risk of infection and the risk of thrombocytopenic bleeding is significant.
Extensive discussions were held regarding the role of cytokines in the care of radiation accident victims, especially the hematopoietic syndrome. There was an agreement about the validity of administering selected growth factors only if there was evidence of a cell population of stem or progenitor cells likely to be present, i.e., not H4 [9] . The group agreed that current management of hematological aspects of ARS does not materially differ from the management requirements of other hematological patients with pancytopenia without radiation exposure. At present, for ARS, cytokines may be administered to appropriately selected victims to mitigate neutropenia to reduce their need for subsequent hospitalization and utilization of what will be limited medical resources and personnel. The U.S./European Consultation Workshop participants felt strongly that both using a particular drug when appropriate and withholding the same when not indicated were equally important, and the use of cytokines should be based on clinical information and not given indiscriminately to everyone with potential radiation exposure.
All patients with less than 500 neutrophils per mm 3 are potential candidates for G or granulocyte-macrophage colony stimulating factor. The drug should be initiated as soon as significant hematological injury data are available. Drug should be continued for 14-21 days or until normalization of the granulocyte count. Specific indications for initiating granulocyte colony stimulating factor therapy include physical dose reconstruction that suggests an exposure of 300 cGy without combined injury or 200 cGy with combined injury. Cytokines should not be used empirically on all patients with radiation exposure.
THE USE OF RESPONSE CATEGORIES WITH A SEVERITY GRADING OF ORGAN DAMAGE TO ESTABLISH THE TYPE OF MEDICAL MEASURES
The medical response that is achievable following a radiation event will be, in large measure, dictated by the size and scope of the event. In general, workshop participants agreed that the goals of care include:
• Do no harm.
• Save lives.
• Decrease short-and long-term morbidity of survivors.
• Provide benefit to as many people as possible given the available resources.
• Deliver medical countermeasures as quickly as possible for both mitigation and treatment, • activate and use resources wisely, including, personnel equipment, space, and therapeutics; this will require optimized concept of operations.
• Use effective mitigating strategies, particularly in a mass casualty event, including sheltering-in-place, public messaging, decontamination, and appropriate early use of medical countermeasures.
• Manage psychosocial concerns.
There was consensus about different types of ''triage'' for different scenarios and settings. In a limited radiological event medical personnel would be available for assistance. In a mass casualty setting there would need to be three levels of triage: an initial rapid triage in the field, secondary triage in the emergency department and a tertiary triage within the hospital assisted by radiation experts. The primary triage efforts specific for radiation victims is based on environmental physical dosimetry. The goal of the primary triage is to rapidly distinguish three groups of victims: those in the immediate need of medical care (in the order of 4-5 Gy or more), those at risk for the hematopoietic syndrome in the next 1-4 weeks with a dose of 2-4 Gy, and those who may need some symptoms management and long-term follow-up but not hematopoietic or clinical treatment. Hospital capacities and facilities must be prepared to accommodate large numbers of patients that require immediate medical care as well as those who will present later with signs and symptoms such as infection and bleeding beyond about 10 days, i.e., those with hematology grades H1 or H2). These later patients show signs and symptoms such as infection and bleeding only beyond about 10 days following exposure.
The METREPOL ''clinical triage'' assigns a patient to a response category and indicates the severity of effect in the four most important organ systems, such as the neurovascular system, the gastrointestinal system, the cutaneous system, and the hematopoietic system and leads to therapeutic interventions [1, 9] . This concept is favored in the USA complemented by the determination of exposure dose by using biodosimetric approaches. The REMM web site [38] provides continual update of radiation medical management knowledge and just-in-time information for medical responders who may not be familiar with the details of ARS. In Europe, Germany for example, when there is a nuclear reactor incident deemed to be a potential public health hazard, predetermined emergency stations are prepared around the nuclear reactors to screen hundreds of persons, register them and select those persons who need further medical assessment [39] .
Additional clinical and laboratory research is needed to develop and validate systems that account for combined multiorgan injuries (i.e., radiation and trauma or burns). Compatible electronic victim tracking tools and electronic health records are essential especially because patients may have to travel to more distant sites for care. Specimen collection and tracking is needed for clinical management, forensics, and research. Guidelines are needed for when to collect what specimen and where to send them for analysis. An increase in laboratory capacity, including mobile laboratories, is absolutely necessary for routine as well as more specialized assays for biodosimetry and radiobioassay. Although the ongoing national planning strategies in the countries of the workshop participants vary from small to large events, planning and concepts of operations developed by the individual countries could be shared among partners, utilizing telecommunication options to bring medical experience to the site of event. Furthermore, guidelines and assistance from national as well as international resources (e.g., IAEA, WHO, Global Health Security Action Group [GHSAG]) will be used when appropriate.
EDUCATION AND TRAINING FOR MEDICAL AND ALLIED STAFF
There was a consensus among the workshop participants about the need for appropriate training programs for doctors and allied medical personnel in the field of radiation medical preparedness and assistance that will participate in the actual care of patients. Training programs should be based on mutually compatible concepts and potential medical measures at the international level. The IAEA and WHO have valuable teaching material and guidelines, many of which deal with radiation protection problems as well as rules and regulations regarding radiation accident management. The concept of some basic education (provided by RITN) with the availability of just-in-time up-to-date information for [24] has been held in Munich (Germany) as a pilot training event. The course included plenary lectures, and ''clinical rounds'' to discuss in depth ''case histories'' from previous radiation accidents. The sessions were extremely productive, because one could ask questions such as ''what happened really,'' ''what measures were taken and when'' and ''what would you have done if such a patient would enter your service.'' Workshop participants encourage the publication of the curriculum from this course as widely as possible. The participants also suggested that educational courses offered at a global level would have similar or identical ''core topics.'' There was a strong support for the idea to have 1 day for case discussion at a time when the ''e-learning part'' has been successfully completed. One should furthermore consider ''audience-specific courses'' such as for oncologists and hematologists, dermatologists, surgeons, nuclear medicine, nurses, and health physicists. Consideration should be given to the possible integration of radiation curriculum into all-hazard approaches to mass casualty.
RESEARCH AND DEVELOPMENT ISSUES FOR POTENTIAL COLLABORATIONS
The state-of-the-art in radiation injury management is largely based on studies of victims of accidental exposure in small events. Accident registries and clinical course of disease-databases are available at the international level (see Oak Ridge REAC/Ts or SEARCH Database developed in Ulm). As these represent ''rare'' diseases of high scientific interest, it is suggested that an international registry of victim clinical histories be created and updated regularly. This would represent an important scientific resource, because it allows study in detail the course of health impairments and the analysis of pathophysiological principles and mechanisms. In addition, it should be possible to create an international network of laboratories to examine the state of knowledge regarding a number of open scientific questions such as mechanisms of multiorgan response to ionizing radiation (acute as well as chronic) and the pathophysiology of multiorgan failure, which would benefit from the analysis of the clinical observations. Furthermore, new experimental work is needed in the field of therapeutic interventions, including the role of growth factor therapy, stem cell transplantation including mesenchymal stem cells and the self-renewal capacities of stem cells of different origin (blood, bone marrow, cord blood, fetal liver) and their interaction with the stem cell niche.
More work is also needed in the field of biodosimetry. It is crucial to come to a consensus regarding the term ''dosimetry''. In biological terms, it is well understood that the term ''dose'' includes cytogenetics, biomarkers, molecular profiling and other methods, some of which depend a great deal on time post exposure, dose-rate and volume of tissue irradiated. It may, however, be very difficult to give a definition of that type of ''dose'' in comparison to the precision with which a ''physical dose'' of exposure can be determined. However, in practical terms it will be important to further develop ''indicators of effect and repair'' as suggested by the National Academy of Sciences [16, 17] and to optimize the interpretation of hematological and cytogenetic indicators. Much of these efforts are on going at the CMCRs and on an international level.
Finally, it may well be useful to think about a tissue sample repository including the storage of bone marrow and blood cell smears and histological material from radiation accident cases as well as from patients after the use of total or partial body exposure for therapeutic reasons.
OVERALL CONCLUSIONS AND NEXT STEPS
There was a strong consensus that there are gaps remaining in the knowledge of the mechanisms of the radiation syndromes and the multiorgan involvement that may result in multiorgan failure. Medical triage will be both symptom-based and dosebased, recognizing that organ dysfunction is related to radiation dose and volume. Furthermore, knowledge from the laboratory and ongoing refinement of the current triage systems will enhance their compatibility and complimentarity. Laboratory and clinical diagnostic assessment tools need to be improved for managing individual victims and for triage. Medical countermeasure use requires ongoing review and updating to optimize patient care so that appropriate measures are used and inappropriate empiric administration of countermeasures is avoided. The development of an effective medical response and the necessary education and training will remain a collaborative work in progress. It is suggested to continue the scientific dialogue between partners such as represented in this workshop.
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